NeoGenomics, Inc. (NASDAQ:NEO) Shares Bought by Swiss National Bank

Swiss National Bank grew its position in NeoGenomics, Inc. (NASDAQ:NEO) by 1.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 252,100 shares of the medical research company’s stock after acquiring an additional 2,600 shares during the quarter. Swiss National Bank owned about 0.20% of NeoGenomics worth $4,155,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Johnson Investment Counsel Inc. acquired a new stake in shares of NeoGenomics during the fourth quarter worth about $168,000. PNC Financial Services Group Inc. raised its stake in NeoGenomics by 5.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 15,610 shares of the medical research company’s stock valued at $257,000 after acquiring an additional 770 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in NeoGenomics during the 4th quarter worth approximately $839,000. Proficio Capital Partners LLC purchased a new position in shares of NeoGenomics in the 4th quarter valued at approximately $372,000. Finally, Keybank National Association OH grew its stake in shares of NeoGenomics by 22.2% in the 4th quarter. Keybank National Association OH now owns 23,092 shares of the medical research company’s stock valued at $381,000 after purchasing an additional 4,197 shares during the last quarter. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on NEO shares. Needham & Company LLC decreased their price target on NeoGenomics from $19.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. Jefferies Financial Group assumed coverage on shares of NeoGenomics in a report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 target price on the stock. The Goldman Sachs Group cut their price target on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Bank of America lowered their price objective on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, February 19th. Finally, Piper Sandler cut their target price on NeoGenomics from $21.00 to $18.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, NeoGenomics has an average rating of “Moderate Buy” and an average price target of $19.60.

NeoGenomics Stock Performance

NASDAQ NEO opened at $9.96 on Wednesday. NeoGenomics, Inc. has a 1-year low of $8.98 and a 1-year high of $19.12. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. The business has a 50 day moving average price of $12.21 and a 200 day moving average price of $14.47. The company has a market capitalization of $1.28 billion, a P/E ratio of -16.06 and a beta of 1.28.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The firm had revenue of $172.00 million during the quarter, compared to analysts’ expectations of $173.40 million. Sell-side analysts expect that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.